High hopes as Inventiva takes NASH contender into phase 3
pharmaphorum
JANUARY 6, 2021
The regulator said it wanted more long-term safety and efficacy data from the REGENERATE study before making a final decision on the drug, which had been expected to be the first entrant into a likely multi-billion dollar market niche. billion annually if approved.
52 
Let's personalize your content